Skip to main content

Table 1 Patient baseline demographics and disease characteristics (FAS)

From: Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study

 

Treatment-naïve

(n = 181)

Previously treated

(n = 77)

Overall

(n = 258)

Age, years, mean ± SD

64.6 ± 9.8

63.0 ± 8.6

64.1 ± 9.5

Female

70 (38.7)

43 (55.8)

113 (43.8)

Country

   

 Argentina

111 (61.3)

25 (32.5)

136 (52.7)

 Colombia

11 (6.1)

7 (9.1)

18 (7.0)

 Costa Rica

3 (1.7)

6 (7.8)

9 (3.5)

 Mexico

56 (30.9)

39 (50.7)

95 (36.8)

Diabetes mellitus

   

 Type 1

18 (9.9)

0

18 (7.0)

 Type 2

163 (90.1)

77 (100)

240 (93.0)

Severity of diabetic retinopathy

   

 Mild

26 (14.4)

10 (13.0)

36 (14.0)

 Moderate

66 (36.5)

23 (29.9)

89 (34.5)

 Severe

76 (42.0)

40 (52.0)

116 (45.0)

 Missing

13 (7.2)

4 (5.2)

17 (6.6)

Comorbiditiesa

   

 Hypertension

76 (42.0)

52 (67.5)

128 (49.6)

 Cataracts

34 (18.8)

19 (24.7)

53 (20.5)

 Hyperlipidemia

18 (9.9)

7 (9.1)

25 (9.7)

 Obesity

8 (4.4)

11 (14.3)

19 (7.4)

BCVA in the study eye, mean ± SD letter score

54.5 ± 19.4

52.9 ± 18.6

54.0 ± 19.2

Categorical BCVA letter score, n (%)

   

 ≥ 70 letters (≥ 20/40 Snellen)

50 (27.6)

17 (22.1)

67 (26.0)

 < 70 letters (< 20/40 Snellen)

131 (72.4)

60 (77.9)

191 (74.0)

 CRT, μm, mean ± SD

388 ± 145

423 ± 146

398 ± 146

  1. BCVA best-corrected visual acuity, CRT central retinal thickness, FAS full analysis set, SD standard deviation
  2. aReported in ≥ 5% of patients. Values are n (%) unless otherwise stated